Professor Nash interviews Dr Roland Grenningloh from the EMD Serono Research and Development Institute, about his paper describing the PK modelling of the novel Bruton’s tyrosine kinase (BTK) inhibitor, evobrutinib, in disease models for RA and lupus.
